Close Menu

Amgen

Decode increased the principal amount of the promissory note to $2.9 million.

Decode expects that the closure and layoffs will cost it around $1.5 million in cash expenditures. It did not say how much it expects to save from the moves.

Steven Casper, director of the master of bioscience degree program at the Keck Graduate Institute of Applied Life Sciences, discusses a recent report assessing the Los Angeles region's life sciences strengths and shortcomings.

Shares of Decode Genetics stock were up nearly 11 percent in trading today following Decode researchers' identification of new prostate cancer risk variants.

The Nasdaq notice comes several months after the firm was almost delisted from the market.

Beyond studying European genetic structural variation, Estonian Genome Project Director Andres Metspalu envisions using the tens of thousands of samples collected so far to better inform healthcare decisions in Estonia, and sees increasing opportunities to take part in drug development activities.

As the first consumer to receive his genome through Illumina's individual genome-sequencing service, Hermann Hauser received his results at an Aug. 20 ceremony at Illumina's San Diego headquarters.

"If approved by the FDA, the DxS TheraScreen: K-RAS Mutation Kit would become a companion diagnostic for use with Erbitux in metastatic colorectal cancer to determine which patients have wild-type KRAS status in the US," DxS said this week.

Pairings: Sep 2, 2009

Premium

Michael Snyder, Earl Collier, Christian Henry, Leroy Hood, George Church

People in the News: Sep 1, 2009

Premium

Jon Faiz Kayyem, James White, Chris Gleeson, Mark Lappe, Francois Mandeville, Earl Collier, David Barker, Lynne Kielhorn

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.